Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 458

1.

Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain.

Cheatle MD, Compton PA, Dhingra L, Wasser TE, O'Brien CP.

J Pain. 2019 Jul;20(7):842-851. doi: 10.1016/j.jpain.2019.01.011. Epub 2019 Jan 26.

PMID:
30690168
2.

Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.

Soares WE 3rd, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD.

Drug Alcohol Depend. 2019 Jan 1;194:482-486. doi: 10.1016/j.drugalcdep.2018.10.035. Epub 2018 Dec 3.

PMID:
30522048
3.

Molecular Genetics and New Medication Strategies for Opioid Addiction.

Hurd YL, O'Brien CP.

Am J Psychiatry. 2018 Oct 1;175(10):935-942. doi: 10.1176/appi.ajp.2018.18030352. Epub 2018 Aug 2.

4.

Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD.

J Psychiatry Neurosci. 2018 Jul;43(4):254-261.

5.

Response to Dr. McAuliffe.

Cheatle MD, Gallagher RM, O'Brien CP.

Pain Med. 2018 May 1;19(5):1102-1103. doi: 10.1093/pm/pny042. No abstract available.

PMID:
29546331
6.

Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.

Shi Z, Wang AL, Jagannathan K, Fairchild VP, O'Brien CP, Childress AR, Langleben DD.

J Psychiatry Neurosci. 2018 Feb 23;43(3):170036. doi: 10.1503/jpn.170036. [Epub ahead of print]

PMID:
29485031
7.

Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision.

Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, O'Brien CP.

J Empir Res Hum Res Ethics. 2018 Apr;13(2):160-172. doi: 10.1177/1556264618755243. Epub 2018 Feb 20.

PMID:
29460668
8.

Evolution of surface catalytic sites on thermochemically-tuned gold-palladium nanoalloys.

Kareem H, Shan S, Lin F, Li J, Wu Z, Prasai B, O'Brien CP, Lee IC, Tran DT, Yang L, Mott D, Luo J, Petkov V, Zhong CJ.

Nanoscale. 2018 Feb 22;10(8):3849-3862. doi: 10.1039/c7nr08748a.

PMID:
29417115
9.

Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.

Frawley T, O'Brien CP, Conneally E, Vandenberghe E, Percy M, Langabeer SE, Haslam K.

Genet Test Mol Biomarkers. 2018 Feb;22(2):98-103. doi: 10.1089/gtmb.2017.0203. Epub 2018 Jan 11.

PMID:
29323541
10.

Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.

Friedmann PD, Dunn KE, Nunes EV, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:31-33. doi: 10.1016/j.jsat.2017.11.008. Epub 2017 Nov 22. No abstract available.

PMID:
29273249
11.

Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision.

Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP.

J Subst Abuse Treat. 2017 Oct;81:66-72. doi: 10.1016/j.jsat.2017.07.015. Epub 2017 Aug 1.

12.

Catalysis beyond frontier molecular orbitals: Selectivity in partial hydrogenation of multi-unsaturated hydrocarbons on metal catalysts.

Liu W, Jiang Y, Dostert KH, O'Brien CP, Riedel W, Savara A, Schauermann S, Tkatchenko A.

Sci Adv. 2017 Jul 26;3(7):e1700939. doi: 10.1126/sciadv.1700939. eCollection 2017 Jul.

13.

Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.

Soares WE 3rd, Wilson D, Rathlev N, Lee JD, Gordon M, Nunes EV, O'Brien CP, Friedmann PD.

J Subst Abuse Treat. 2018 Feb;85:66-69. doi: 10.1016/j.jsat.2017.05.009. Epub 2017 May 12.

PMID:
28576389
14.

Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.

Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:49-55. doi: 10.1016/j.jsat.2017.04.016. Epub 2017 Apr 23.

15.

Low Risk of Producing an Opioid Use Disorder in Primary Care by Prescribing Opioids to Prescreened Patients with Chronic Noncancer Pain.

Cheatle MD, Gallagher RM, O'Brien CP.

Pain Med. 2018 Apr 1;19(4):764-773. doi: 10.1093/pm/pnx032.

PMID:
28379504
16.

Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.

Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP.

Addiction. 2017 Aug;112(8):1440-1450. doi: 10.1111/add.13807. Epub 2017 Apr 12.

17.

Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?

Friedmann PD, Wilson D, Nunes EV, Hoskinson R Jr, Lee JD, Gordon M, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O'Brien CP.

J Subst Abuse Treat. 2018 Feb;85:61-65. doi: 10.1016/j.jsat.2017.01.018. Epub 2017 Feb 22.

18.

Image-guided intrathecal baclofen pump catheter implantation: a technical note and case series.

Robinson S, Robertson FC, Dasenbrock HH, O'Brien CP, Berde C, Padua H.

J Neurosurg Spine. 2017 May;26(5):621-627. doi: 10.3171/2016.8.SPINE16263. Epub 2017 Feb 3.

PMID:
28156208
19.

Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

Gordon MS, Vocci FJ, Fitzgerald TT, O'Grady KE, O'Brien CP.

Contemp Clin Trials. 2017 Feb;53:130-136. doi: 10.1016/j.cct.2016.12.015. Epub 2016 Dec 20.

20.

Selective Hydrogenation of Acrolein Over Pd Model Catalysts: Temperature and Particle-Size Effects.

O'Brien CP, Dostert KH, Schauermann S, Freund HJ.

Chemistry. 2016 Oct 24;22(44):15856-15863. doi: 10.1002/chem.201602021. Epub 2016 Sep 13.

PMID:
27621113

Supplemental Content

Loading ...
Support Center